W1805 Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in NaïVE Patients
Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Uchenna H. Iloeje(Bristol-Myers Squibb (United States)), Michael Wichroski(Bristol-Myers Squibb (Germany)), Dong Xu(Bristol-Myers Squibb (United States)), Ronald E. Rose(Bristol-Myers Squibb (United States)), Betsy J. Eggers(Bristol-Myers Squibb (United States)), Carl J. Baldick(Bristol-Myers Squibb (United States)), Richard B. Wilber(Bristol-Myers Squibb (United States)), Kevin A. Pokornowski(Bristol-Myers Squibb (United States)), H. Brett‐Smith(Bristol-Myers Squibb (United States)), Jie Fang(Chinese Academy of Sciences), Ulysses Diva(Korean Red Cross)
Cited by 25
Related Papers
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
|Gastroenterology|2006|1.5k
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
|Hepatology|2009|815
Global Epidemiology of Hepatitis B Virus
|Journal of Clinical Gastroenterology|2004|601
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
|Hepatology|2006|348